Headlines
-
Many stores still not stocking Naloxone
Friday | May 3 2024NEW research from the Monash Addiction Research Centre has highlighted a critical shortfall in the availability of Naloxone, a life-saving medication that reverses opioid overdoses, across community pharmacies in Australia's most populous states.
-
Senate inquiry hearing on vaping bill
Thursday | May 2 2024THE Senate's Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
-
Cardiac drug on the PBS
Thursday | May 2 2024PFIZER Australia's Vyndamax (tafamidis) is now listed on the PBS for treating fatal heart conditions related to amyloid disorders.
-
Cardio cuts death by 20%
Thursday | May 2 2024A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
-
Pharmacists at higher risk of suicide
Wednesday | May 1 2024NEW data from the Australian Institute of Health and Welfare has revealed around 43% (or 8.5 million) of Australians aged 16-85 have experienced a mental disorder at some point in their lives.
-
Heart muscle disease drug gets listed
Wednesday | May 1 2024PHARMACISTS can now dispense the newly listed Camzyos (mavacamten) drug to patients who are prescribed the medication.
-
Guild’s ACCC submission
Tuesday | Apr 30 2024THE Pharmacy Guild of Australia has formally expressed its concerns regarding the potential merger between Sigma and Chemist Warehouse (PD 07 Dec 2023) to the Australian Competition and Consumer Commission (ACCC).
-
PBS listing for Verzenio
Tuesday | Apr 30 2024FROM 01 May, pharmacists will be able to dispense Verzenio (abemaciclib) through the PBS to treat Australian patients with an invasive form of early breast cancer that is at high risk of recurring after initial treatment.
-
BCNA urges swift action
Monday | Apr 29 2024BREAST Cancer Network Australia (BCNA) has welcomed a PBAC recommendation to subsidise the breast cancer drug Enhertu (trastuzumab deruxtecan) for HER2-low metastatic breast cancer on the PBS.
-
Bol to speak at PC2024
Monday | Apr 29 2024PHARMACY Connect (PC2024) has revealed that Olympian Peter Bol will be sharing his journey from adversity to athletic greatness at the conference in Sep in Sydney.
